跳至主要内容
临床试验/NCT04452513
NCT04452513已完成不适用

A Prospective Clinical Study of Phenylketonuria (PKU)

BioMarin Pharmaceutical14 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2019年10月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32
试验地点
14
主要终点
Change in Plasma Phe Levels

研究概览

简要总结

This is a study for adults and children ≥ 14 years old who have Phenylketonuria (PKU) with uncontrolled plasma Phe levels. No clinical intervention or study drug is provided by BioMarin in this study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects with diagnosis of PKU which is a condition characterized by PAH deficiency
  • Ability and willingness to maintain dietary protein intake consistent with baseline intake
  • Willingness and capable per investigator opinion to comply with study procedures and requirements
  • Plasma Phe Levels > 600umol/L

排除标准

  • Clinically significant liver dysfunction or disease
  • Prior treatment with gene therapy
  • Any condition that, in the opinion of the investigator or Sponsor, would prevent the subject from fully complying with the requirements of the study

结局指标

主要结局

Change in Plasma Phe Levels

时间窗: through study completion, an average of 2 years

次要结局

  • Change in dietary protein intake from medical and intact food(through study completion, an average of 2 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验